Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (220 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: mgreceivefailurecompleteend
  Phrases that lowered it: kggeneralbodysugammadexbased on
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: not given (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 9 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Blinding: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 9.5% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 80 (lowers risk) · Who can join
• Sponsor's past trials: 8 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients NCT01911520 · started 2011 · scored riskier than 46% of active trials completed
• Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery NCT02713113 · started 2015 · scored riskier than 8% of active trials completed
• Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) NCT00758485 · started 2008 · scored riskier than 22% of active trials completed
• Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) NCT00675792 · started 2008 · scored riskier than 22% of active trials completed
• Sugammadex-dosing in Bariatric Patients NCT01570179 · started 2012 · scored riskier than 16% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.